News and Trends 26 Jul 2022 Oxford Biomedica sets up new project and signs LSA Oxford Biomedica plc, a UK-based gene and cell therapy group, has initiated a new project with Orchard Therapeutics utilizing the company’s LentiStable technology. The group also announced the signing of a new licence and supply agreement (LSA) with an undisclosed US-based private biotech company advancing a new generation of adoptive cell therapies. LentiStable technology As […] July 26, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Catalonia health startup investments in 2022 top €296M to overtake 2021 tally Life sciences organization Biocat says midyear investment in startups in the BioRegion of Catalonia in Spain is 2.5 times higher than the same period last year, at €296 million ($301 million). The total for the entire year 2021 was €238 million ($242 million). The first semester included a round of €100 million ($101.8 million) by […] July 26, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Israeli foodtech company develops zero-waste plant protein extraction A novel, waste-free protein extraction method that completes the sustainability loop through the sustainability practice of upcycling has been created by Acre, Israel-Gavan Technologies, Ltd. The foodtech start-up supports the circular economy by positioning total plant extraction at the core of its operations. Itai Cohen, CEO and co-founder of Gavan, said: “Our new, multistep technological […] July 26, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA A drug candidate for unresectable or metastatic breast cancer has been accepted by the US Food and Drug Administration (FDA). The drug is being jointly developed and commercialized and the result of a high-profile partnership between AstraZeneca and Daiichi Sankyo. Enhertu (trastuzumab deruxtecan) is a specifically engineered HER2-directed antibody drug conjugate (ADC). Acceptance The companies received […] July 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens Finnish immunotherapy company Valo Therapeutics Oy (ValoTx) has obtained exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. Valo said the deal will enable the rapid […] July 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 26 Jul 2022 How DNA sequencing can safeguard against biodiversity loss Preserving Earth’s biodiversity is crucial as we rely on healthy ecosystems for many services, from clean air and water to protection from floods and pandemics. DNA sequencing is an invaluable tool for characterizing biodiversity and informing conservation efforts. In Earth’s history, there have been five major mass extinction events — the most recent of which […] July 26, 2022 - 8 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Ginkgo acquires Zymergen for $300M and picks up Bayer facility for $83M U.S. cell programming company Ginkgo Bioworks has signed definitive agreements to acquire two teams and technologies. The deals are with Bayer and Zymergen. Bayer transaction The company confirmed the previously announced transaction with Bayer to expand Ginkgo’s platform capabilities in agricultural biologicals. Ginkgo will acquire Bayer’s 175,000-square-foot West Sacramento Biologics Research & Development site, team, […] July 26, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization The Committee for Medical Products for Human Use (CHMP) has recommended the European Commission (EC) make a marketing authorization under exceptional circumstances for a drug to treat a rare condition characterized by brain dysfunction. The drug is called NULIBRY (fosdenopterin) for injection therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. […] July 25, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Bavarian Nordic gets European monkeypox approval for smallpox vaccine Danish company Bavarian Nordic A/S says the European Commission (EC) has extended the marketing authorization for the company’s smallpox vaccine, IMVANEX, to include protection from monkeypox and disease caused by vaccinia virus. The approval, which follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) on July 22, 2022, is valid […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Drug for acute treatment of social anxiety disorder did not meet primary endpoint A nasal spray to treat anxiety did not meet its primary endpoint and was not significantly better than the placebo given during a phase 3 clinical trial. Vistagen Therapeutics Inc’s drug, PH94B, was designed to treat people living with anxiety, depression and other central nervous system (CNS) disorders announced the topline results on Friday (July […] July 25, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 NEOsphere Biotechnologies closes financing round NEOsphere Biotechnologies GmbH has completed a series A financing round to expand its proteomics platform, which screens extensive small-molecule libraries for degraders of pathogenic proteins previously considered undruggable. The funding amount was not disclosed, however, the company told us there were four investors, with the main amount coming from Munich-based Ventura BioMed Investors GmbH. NEOSphere […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Macao university research finds mRNA vaccine booster offers more protection against Omicron variants A study in Macao has found people taking the BioNTech mRNA vaccine as the third booster dose produce more neutralizing antibodies against Omicron variants. The study, led by Daniel Baptista-Hon, assistant professor at the Faculty of Medicine at the Macau University of Science and Technology (M.U.S.T.), and Ligong Lu, director of Zhuhai People’s Hospital, was […] July 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email